News | August 24, 2021
Lupin launches Luforbec to treat asthma & COPD in UK
It is the first branded generic alternative to Fostair 100/6 pMDI
It is the first branded generic alternative to Fostair 100/6 pMDI
The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months
Collaboration combines Lupin’s inhaler manufacturing capabilities with ERN’s strong commercial presence to expand access to respiratory care
The facility sets a new benchmark in respiratory diagnostics
The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
